Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett’s esophagus: An Italian experience

Conio, Mássimo

doi:10.3748/wjg.v11.i42.6650

Cited by 75 publications

(44 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data demonstrated the efficacy of EMR for Barrett's dysplasia and IMC. On the other hand CBE-EMR seems to be associated with more complications [186][187][188][189][190][191][192][193][194][195][196][197][198][199][200]. Rates of bleeding and perforation in large EMRs increased up to 19% and 11% respectively, and appear to be higher than those for ablative modalities [195,198].…”

Section: Non Ablative Modalities (Endoscopic Resection-emr)mentioning

confidence: 92%

“…Therefore, EMR has been accepted method for BE with small and/or raised lesions of HGD or IMC [172]. Independently of endoscopic techniques, the most common complications of EMR are bleeding and esophageal stricture formation, but most of them can be treated successfully by endoscopy [186][187][188][189][190][191][192][193][194][195][196][197][198][199]. Perforation has been reported in 1-2.6% of the patients, but seems to decrease with more experience.…”

Section: Non Ablative Modalities (Endoscopic Resection-emr)mentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and Management of Barrett’s Esophagus with and Without Dysplasia

Vladimirov¹,

Ivanova²,

Terziev³

2013

Endoscopy of GI Tract

View full text Add to dashboard Cite

Section: Non Ablative Modalities (Endoscopic Resection-emr)mentioning

confidence: 92%

Section: Non Ablative Modalities (Endoscopic Resection-emr)mentioning

confidence: 99%

Diagnosis and Management of Barrett’s Esophagus with and Without Dysplasia

Vladimirov¹,

Ivanova²,

Terziev³

2013

Endoscopy of GI Tract

View full text Add to dashboard Cite

“…Conio et al (109) and Mino-Kenudson et al (110) reported a changed histological diagnosis in 26 and 37%, respectively, of patients with BE undergoing EMR. Studies suggest that EMR may successfully eliminate early ADC with a low complication rate but relapse rates of 25-30% during the first 3 years when used as single therapy in patients with HGD or intramucosal ADC (111).…”

Section: Endoscopic Mucosal Resection (Emr)mentioning

confidence: 99%

Barrett´s esophagus: a review

Ciriza-de-los-Ríos

2010

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

“…Unlike other ablative methods, EMR permits histological assessment of the whole lesion permitting definition of lateral extent and depth. It alters the pathological staging in BO in 26-37% of patients [Conio et al 2005;Mino-Kenudson et al 2005]. EMR is suitable for short segments of BO, early OA and particularly useful for visible lesions.…”

Section: Radiofrequency Ablationmentioning

confidence: 99%

Management of Barrett’s oesophagus and intramucosal oesophageal cancer: a review of recent development

Rajendra

2012

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Barrett’s oesophagus is the most important and recognizable precursor lesion for oesophageal adenocarcinoma, which is the one of the fastest growing cancers in the Western World. The incidence of oesophageal adenocarcinoma has increased 600% in the United States between 1975 and 2001 and is thought to represent a real increase in burden rather than a result of histologic or anatomical misclassification or overdiagnosis. Thus, the cancer risk in Barrett’s oesophagus has to be managed and involves prevention (surveillance endoscopy), treating underlying gastroesophageal reflux disease (medically and or surgically) and endoscopic therapy to remove diseased epithelium in appropriate patient subgroups. In the last decade, new developments in imaging and molecular markers as well as an armamentarium of novel and effective endoscopic eradication therapy has become available to the endoscopist to combat this exponential rise in oesophageal adenocarcinoma. Paradoxically, the cancer risk in Barrett’s oesophagus gets progressively downgraded which raises fundamental questions about our understanding of the known and unknown risk factors and molecular aberrations that are involved in the Barrett’s metaplasia–dysplasia–carcinoma sequence. Future research has to be directed at these areas to fine tune our screening and surveillance programs to identify more accurately the high-risk group of progressors to oesophageal adenocarcinoma who would benefit most from endoscopic therapy.

show abstract

Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett’s esophagus: An Italian experience

Abstract: In the medium term, EMR is effective and safe to treat HGD and/or IMC within BE and is a valuable staging method. It could become an alternative to surgery.

Cited by 75 publications

References 37 publications

Diagnosis and Management of Barrett’s Esophagus with and Without Dysplasia

Diagnosis and Management of Barrett’s Esophagus with and Without Dysplasia

Barrett´s esophagus: a review

Management of Barrett’s oesophagus and intramucosal oesophageal cancer: a review of recent development

Contact Info

Product

Resources

About